Related Experiment Video

Updated: Dec 28, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.8K

Anticoagulation in Patients with Atrial Fibrillation and Coronary Artery Disease

Fahad Abdullah Alkindi1, Ihsan Mahmoud Rafie1

  • 1Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Heart Views : the Official Journal of the Gulf Heart Association
|February 22, 2020
PubMed

Insights

Managing antithrombotic therapy for atrial fibrillation patients with coronary artery disease requires balancing bleeding and clotting risks. Recent trials compare dual-therapy versus triple-therapy strategies for these complex patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Managing antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) for coronary artery disease (CAD) presents significant clinical challenges.
  • These patients often require both oral anticoagulation (for AF) and antiplatelet therapy (for CAD), necessitating a careful balance between thromboembolic and bleeding risks.

Purpose of the Study:

  • To review and analyze recent clinical trials evaluating antithrombotic strategies in patients with both AF and CAD undergoing PCI.
  • To compare the efficacy and safety of dual-therapy (oral anticoagulant plus one antiplatelet agent) versus triple-therapy (oral anticoagulant plus two antiplatelet agents) regimens.

Main Methods:

  • Systematic review and meta-analysis of major clinical trials comparing different antithrombotic strategies.
  • Analysis focused on patient populations with established atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention.

Main Results:

  • Dual-therapy strategies may offer a reduced bleeding risk compared to traditional triple-therapy.
  • Thromboembolic event rates need careful evaluation across different treatment arms to establish optimal risk-benefit profiles.

Conclusions:

  • The optimal antithrombotic strategy for patients with AF undergoing PCI for CAD requires individualized assessment of bleeding and thrombotic risks.
  • Ongoing research and large clinical trials are crucial for refining treatment guidelines and improving patient outcomes.

Keywords:
Antithrombotic therapyatrial fibrillationpercutaneous coronary angiogramstroke

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.3K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
186
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
174
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K